🏢 Avantor’s new innovation center boosts capacity for research on biomanufacturing, supporting various therapies. Keybl highlights growth in cell and gene therapies, and the importance of adapting to market changes.
💡 AI tools are being developed to enhance decision-making for customers in the biomanufacturing space.
Introduction:
The article features an interview with Jerry Keybl, the Senior Vice President of Biopharma Products and Strategy at Avantor, discussing key trends in biomanufacturing and strategies for navigating market shifts. This conversation occurs before the Interphex meeting in New York City, where Avantor plans to showcase its advancements in the biologics sector.
- Avantor has recently increased the capacity of its European manufacturing facility and opened a new innovation center in Bridgewater, NJ, enhancing its research and development capabilities.
- The company aims to highlight scalability, flexibility, and efficiency in bioprocessing solutions at the Interphex meeting, showcasing innovations like improved magnetic mixing systems.
- Key growth areas for Avantor include advancements in cell and gene therapies, specifically with tools like tangential flow filtration systems and environmentally friendly reagents.
- Trends in biomanufacturing include the rising focus on diverse therapeutic modalities such as antibody-drug conjugates and viral vectors, as well as an adaptive approach to bioprocessing to meet varying manufacturing needs.
- Keybl emphasizes the importance of maintaining patient access to therapies despite economic and political challenges, showcasing Avantor’s global presence as a strategic advantage in meeting customer needs.
Conclusion:
The discussion with Jerry Keybl underscores Avantor’s commitment to innovation and efficiency in the evolving biotherapeutics landscape. The company’s strategic investments in facilities and technologies, alongside an adaptable approach to market demands, position it favorably to address the challenges and opportunities in biomanufacturing moving forward.
